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Abstract
Two familial forms of colorectal cancer (CRC), Lynch syndrome (LS) and familial ade-
nomatous polyposis (FAP), are caused by rare mutations in DNA mismatch repair
genes (MLH1, MSH2, MSH6, PMS2) and the genes APC and MUTYH, respectively. No
information is available on the presence of high‐risk CRC mutations in the Romanian
population. We performed whole‐genome sequencing of 61 Romanian CRC cases
with a family history of cancer and/or early onset of disease, focusing the analysis
on candidate variants in the LS and FAP genes. The frequencies of all candidate
variants were assessed in a cohort of 688 CRC cases and 4567 controls. Immunohis-
tochemical (IHC) staining for MLH1, MSH2, MSH6, and PMS2 was performed on
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tumour tissue. We identified 11 candidate variants in 11 cases; six variants in
MLH1, one in MSH6, one in PMS2, and three in APC. Combining information on the
predicted impact of the variants on the proteins, IHC results and previous reports,
we found three novel pathogenic variants (MLH1:p.Lys84ThrfsTer4, MLH1:
p.Ala586CysfsTer7, PMS2:p.Arg211ThrfsTer38), and two novel variants that are unli-
kely to be pathogenic. Also, we confirmed three previously published pathogenic LS
variants and suggest to reclassify a previously reported variant of uncertain signifi-
cance to pathogenic (MLH1:c.1559‐1G>C).
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1 | INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer worldwide
and the fourth most common cause of death from cancer,1 causing
an estimated 8% of all cancer deaths. Lynch syndrome (LS) or hered-
itary nonpolyposis CRC is an autosomal dominant syndrome that
accounts for about 1%‐3% of all CRC cases.2,3 LS is the most com-
mon inherited cause of CRC and is caused by pathogenic germline
mutations in one of four DNA mismatch repair (MMR) genes (MLH1,
MSH2, MSH6, and PMS2).4 Carriers of LS mutations have an esti-
mated 25%‐75% life‐time risk of CRC as well as increased risk of
several other cancer types, including endometrial and ovarian can-
cer.5 Due to the low frequency of LS and heterogeneity in pheno-
typic expression, it has proven difficult to accurately establish
population prevalence and to assess the penetrance of LS
mutations.6
About 15% of CRC cases are somatically hypermutated as a con-
sequence of MMR deficiency. Of these, 1%‐3% are due to LS while
most of the remaining MMR‐deficient tumours have somatic inacti-
vation of MLH1 via hypermethylation of the gene promoter.7 In
MMR‐deficient tumours, both copies of the same MMR gene have
been inactivated, resulting in no production of the respective protein
product. MMR‐deficient tumours exhibit several clinical characteris-
tics that have implication for therapy, in particular with regard to the
use of immune system modulators.8 Therefore, universal screening
of CRC tumours, using microsatellite testing or immunohistochem-
istry (IHC) for the MMR proteins, has been recommended by several
groups in Europe and the United States.9
To date, nothing is known about the prevalence of LS in the
Romanian population and no mutations have been reported. The
ROMCAN Project (“Genetic Epidemiology of Cancer in Romania”)
started in 2012 with the major aim of characterizing genetic risk fac-
tors for CRC, breast cancer (BRC), prostate cancer (PrCa), and lung
cancer (LuCa) in the Romanian population. The second goal of the
ROMCAN Project is to define high‐risk groups for whom specific
preventive measures can be implemented.
The objective of this study is to start assessing the impact of LS
variants in CRC in Romania and provide a framework for screening
in high‐risk families. Our present study was designed to identify
high‐risk mutations in six CRC genes using whole‐genome sequenc-
ing (WGS). The frequencies of all candidate variants were then
assessed in the entire ROMCAN cohort of 688 CRC cases and 4567
controls. In addition to the four MMR genes, we focused the analy-
sis on mutations in two other CRC‐associated genes, APC and
MUTYH.10
2 | MATERIALS AND METHODS
2.1 | Selection of CRC cases for WGS
We selected 61 CRC cases from the ROMCAN and ProMark pro-
jects sample collection, a hospital‐based sample set of 4567 cancer
cases and controls recruited from five major hospitals in Bucharest
between 2008 and 2017. The 61 CRC cases were selected using the
following criteria: age at diagnosis lower than 40 years or family his-
tory of CRC, endometrial or gastrointestinal tumours. Two of the
selected cases are of Roma origin. Both ProMark and ROMCAN are
large‐scale genetic epidemiological studies investigating the profile of
respectively PrCa and BRC, CRC, LuCa and PrCa in the Romanian
population.
All subjects gave written informed consent prior to enrolment
and accepted the use of personal and clinical data and biological
samples for genetic research. The Bioethical Committee of the Medi-
cal School “Carol Davila” approved the study protocols. Trained
interviewers performed face‐to‐face interviews, using standardized
questionnaires, to collect personal data (ethnicity, marital status, edu-
cation, height, and weight), lifestyle data (occupation, smoking his-
tory, coffee and tea consumption), and medical history (personal and
familial). A description of relevant epidemiological and clinical infor-
mation can be found in Table 1.
2.2 | Whole‐genome sequencing and variant calling
DNA isolated from buccal samples from the 61 individuals was
subjected to WGS to a targeted average depth of 30x. The sam-
ples were prepared following the TruSeq Nano sample preparation
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method and sequenced on Illumina HiSeq X machines. Sequencing
reads were aligned to build 38 of the human reference sequence
(GRCh38) using the Burrows‐Wheeler Aligner (BWA).11 Alignments
were merged into a single BAM file and marked for duplicates
using Picard.12 Only nonduplicate reads were used for the down-
stream analyses. Variants were called using version 3.8‐0 of
the Genome Analysis Toolkit (GATK),13 using a multisample
configuration.
2.3 | Variant annotation and filtering
Variants were annotated using release 8.0 of the Variant Effect Pre-
dictor (VEP‐Ensembl).14 To filter out variants over a certain fre-
quency threshold, we used a reference set of 38 000 Icelandic
individuals whole‐genome sequenced at deCODE genetics, an exten-
sion of a previously described set of 15 220 WGS Icelanders.15
None of the variants described here had any carriers in the Icelandic
dataset. Additional frequency filtering was performed using alleles
from publicly available datasets of the Exome Aggregation Consor-
tium.16
2.4 | Genetic analysis
Only rare (below 1% allelic frequency) coding and splice region vari-
ants were considered, including variants with predicted high (stop,
frameshift, and splice essential) and moderate (missense, in‐frame,
and splice region) impact on protein function. We focused on single‐
nucleotide polymorphisms and small indels (< 20 base pairs). We
analysed pathogenic and expected pathogenic mutations in six
genes, defined by the American College of Medical Genetics to be
high‐risk genes in CRC: MLH1, MSH2, MSH6, PMS2, APC, and
MUTYH.17
2.5 | Frequency assessment in the Romanian
population
All 11 coding variants found in the study were genotyped in the
entire ROMCAN sample collection of 688 CRC cases, 254 BRC
cases, 1457 PrCa cases, 1317 LuCa cases, and 1409 cancer‐free
controls. The variants were genotyped using one of two assays: Cen-
taurus12 or KASP.13 Sanger sequencing was used for one variant that
failed in both assays. The primer sequences for the assays are listed
in Table S1.
2.6 | Immunohistochemistry
Paraffin blocks with tumour samples from all 11 carriers of vari-
ants in the LS genes were collected and sections from them
stained for MLH1, MSH6, PMS2 to assess if the protein was pre-
sent. Immunohistochemistry was performed on 3 μm sections. Fol-
lowing deparaffinization in xylene, samples were rehydrated in
ethanol and subjected to heat‐induced epitope retrieval (Tris/EDTA
buffer, pH 9) in a 98.2°C water bath. Endogenous peroxidase
activity was blocked with 3% hydrogen peroxide (DAKO). After
incubation with the respective primary antibodies for 30 minutes
at 20°C, EnVision FLEX Kit (DAKO ref:K8000) was used for
detection.
Antibodies used were: Anti‐Human MutL Protein Homolog 1,
Clone ES05, (DAKO ref:IR079), Anti‐Human Postmeiotic Segregation,
Clone EP51 (DAKO ref:IR087, Anti‐Human MutS Protein Homolog
6, Clone EP49 (DAKO ref:IR086).18
TABLE 1 Patient and tumour characteristics of the 61 CRC cases
selected for whole‐genome sequencing
N %
Male 36 59.0
Female 25 41.0
TNM stage
T0 3 4.9
Tis 3 4.9
T1 3 4.9
T2 3 4.9
T3 34 55.7
T4 4 6.6
T—NA 11 18.0
N0 26 42.6
N1 15 24.6
N2 9 14.8
NA—N 11 18.0
M0 45 73.8
M1 5 8.2
M—NA 11 18.0
SNOMED code
M8480/3 2 3.3
M8140/3 59 96.7
ICD10 code
C18.0 3 4.9
C18.2 5 8.2
C18.3 2 3.3
C18.4 5 8.2
C18.5 2 3.3
C18.6 6 9.8
C18.7 13 21.3
C18.8 1 1.6
C19.9 8 13.1
C20.9 16 26.2
Age at diagnosis
30‐39 years 9 14.8
40‐49 years 16 26.2
50‐59 years 14 23.0
60‐69 years 15 24.6
70‐79 years 7 11.5
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3 | RESULTS
Sequencing of the 61 CRC patients revealed 11 rare coding variants
in CRC genes: six variants in MLH1, one variant in MSH6, one variant
in PMS2, and three variants in APC. We examined literature and clin-
ical trial submission data collected by ClinVar19 with respect to
pathogenicity, six out of the 11 variants have been previously
reported by ClinVar. All six previously reported variants have a fre-
quency lower than 1% in the ExAC database.16
For each of the 11 variants, we assessed whether the variants
had a high or moderate impact on protein function, based on the
location of the mutation within its gene and its predicted molecular
consequences (Table 2); frameshift, splice donor or acceptor and
stop‐codon gain variants are predicted to have a high impact while
in‐frame, missense and splice region variants are predicted to have a
moderate impact. To assess the frequencies of the variants in the
Romanian population, we genotyped all 11 variants in the ROMCAN
cohort: 688 colorectal cases and 4567 cases with cancers other than
CRC and controls (254 BRC cases, 1457 PrCa cases, 1317 LuCa
cases, and 1409 cancer‐free controls) (Table 3). To test for loss of
protein product, we stained MLH1, MSH6, and PMS2 in tumour tis-
sue from paraffin blocks, collected from the carriers of the coding
variants.
We assessed the pathogenicity of these variants in the Romanian
population based on IHC results, predicted protein effect and anno-
tation in ClinVar and InSIGHT databases (Table 2, APRP, assessment
of pathogenicity in the Romanian population).
We divide our results into two categories; novel variants and
previously documented variants. We summarized all reports regard-
ing the pathogenicity of the previously reported variants in Table S2,
using the output from the ClinVar database. An overview of personal
and familial history of cancer for the 11 carriers is listed in Table 4.
3.1 | Novel variants
3.1.1 | MLH1
MLH1: c.251_255delAACTG is a frameshift variant with predicted
amino acid change Lys84ThrfsTer4, and consequently assessed as a
high impact variant. IHC staining of the tumour of the carrier of this
mutation revealed a loss of MLH1 protein, indicating pathogenicity.
We classify this variant as a pathogenic for LS based on the impact
of the frameshift mutation and IHC results, classifying this variant as
a tier II, level D based on the recommendations of the American Col-
lege of Medical Genetics and Genomics (ACMG).
MLH1:c.1755dupT is a frameshift variant with predicted amino
acid change Ala586CysfsTer7, and consequently annotated as a high
impact variant. IHC staining of the patient's tumour revealed a loss
of MLH1 protein. Based on the impact of the frameshift mutation
and IHC result, we classify this variant as a pathogenic for LS, as a
tier II, level D based on the recommendations of the ACMG.
MLH1:c.2104‐6T>C is a splice region variant, and consequently
annotated as having moderate impact. IHC staining of the patient's
tumour did not reveal a loss of MLH1 protein expression. Our results
do not support that his variant should be classified as pathogenic.
We classify this variant as a tier III based on the recommendations
of the ACMG.
3.1.2 | PMS2
The frameshift variant PMS2:c.630dupA results in the predicted pro-
tein change Arg211ThrfsTer38, and consequently annotated as hav-
ing high impact. IHC staining showed a loss of PMS2 protein
expression in the carrier of this variant. The patient was diagnosed
at age 44 and had extensive family history of gastrointestinal tract
cancers. Based on the impact of the frameshift mutation, and IHC,
we classify this variant as pathogenic for LS, we classify it as tier II,
level D based on the recommendations of the ACMG.
3.1.3 | APC
The missense variant APC:c.5116T>A results in a protein change of
Ser1706Thr, and is consequently annotated as having moderate
impact. It has not been previously reported either by ClinVar or
other studies. According the clinical significance guidelines for classi-
fication of sequence variants, we consider this variant to be likely
benign, we classify it as tier IV, based on the recommendations of
the ACMG. The carrier of this mutation also had a previously
reported APC variant of uncertain significance (VUS), APC:
c.2780C>G (Ala927Gly) described below.
3.2 | Previously documented variants
3.2.1 | MSH6
MSH6:c.3202C>T (RS63749843), is a stop‐gained variant, assessed
as a high impact variant with a protein change of Arg1068Ter. This
variant was previously reported as pathogenic in ClinVar by 10 dif-
ferent submitters involved in clinical testing and research. Tumour
sample from the carrier of this variant had loss of MSH6 protein
expression, further supporting its pathogenicity. We classify this vari-
ant as a tier II, level D based on the recommendations of the
ACMG.
3.2.2 | MLH1
MLH1:c.1148T>C (RS141344760) is a missense variant, and conse-
quently of moderate predicted impact, resulting in a protein change
of Met383Thr. IHC staining of the carrier's tumour showed positive
protein expression for MLH1. The variant was previously reported as
being of uncertain significance in ClinVar by five different submitters
from clinical testing and research and our results do not support
pathogenicity. We classify this variant as a tier III based on the rec-
ommendations of the ACMG.
MLH1:c.1559‐1G>C is a splice acceptor variant, annotated as
high impact. This was the only candidate mutation found in two
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CRC cases. The tumour samples from both carriers had lost MLH1
protein and both had documented family history or CRC. The variant
has been reported previously by two different submitters as likely
pathogenic for LS and our results indicate that the variant is patho-
genic. We classify this variant as a tier II, level D based on the rec-
ommendations of the ACMG.
MLH1:c.2041G>A (rs63750217) is a missense with a predicted
protein change of Ala681Thr, and consequently of moderate impact.
The tumour of the carrier had loss of MLH1 protein staining. This
variant was previously reported as pathogenic in ClinVar by nine dif-
ferent submitters from clinical testing and research. In addition,
OMIM has classified the variant as pathogenic for LS II. We classify
this variant as a tier II, level D based on the recommendations of the
ACMG.
3.2.3 | APC
APC:c.2780C>G (rs587781500) results in the amino acid change
Ala927Gly and consequently of moderate impact. It was previously
reported as a VUS in ClinVar by four different submitters from clini-
cal testing. We classify this variant as tier III based on the recom-
mendations of the ACMG. As mentioned above, the carrier also had
another likely benign variant in APC, APC:c.5116T>A (Ser1706Thr).
APC:c.3682C>T is a stop‐gained variant resulting in the protein
change Gln1228Ter, and consequently of high impact. It was
reported in ClinVar by a single submitter as pathogenic for familial
multiple polyposis syndrome and was found in a recent study inves-
tigating somatic APC mutations and loss of heterozygosity status for
630 patients with sporadic CRC.14 We classify this variant as a tier
II, level D based on the recommendations of the ACMG.
4 | DISCUSSIONS
This study is the first assessment of rare variants underlying LS in
CRC patients in Romanians. We identify new variants specific to the
Romanian population and show that some variants previously
reported to be pathogenic in other populations also occur in Roma-
nia.
We identified three novel pathogenic variants, two novel variants
that are unlikely to be pathogenic. Also, we confirmed three previ-
ously published pathogenic variants and suggest to reclassify a vari-
ant previously classified as VUS as pathogenic. Due to study
limitations, we were not able to classify the three APC variants iden-
tified in the Romanian population. We note that out of the two rare
missense variants in APC identified in the same individual, we clas-
sify one as a likely benign variant based on ACMG's guidelines for
classification of sequence variants.20 The other variant, p.Ala927Gly,
has been reported previously as a VUS, but we note that it is
located within a critical domain, intolerant to mutations. Our present
study is the first one, to our knowledge, to examine rare sequence
variants associated with CRC in the Romanian population.
In total, we identified six pathogenic variants, one nonpathogenic
variant and four variants of uncertain significance in the Romanian
population. In order to determine the prevalence of these variants in
Romania, we assessed the frequencies of the 11 variants in the full
ROMCAN cohort. As described in Table 3, none of the mutations
were found in more than 1 CRC patients except for MLH1:c.1559‐
1G>C. Our results do not suggest any strong association between
the 11 variants identified here and BRC, LuCa or PrCa.
Identification of LS variants in the Romanian population is impor-
tant in order to reduce the incidence and mortality of this multi-
cancer disorder. Our present study is the largest effort, to our
knowledge, to examine the genetic profile of this pathology in East-
ern Europe. Due to study limitations, we were not able to extrapo-
late any other clinical observations, and we emphasize the need for
future follow‐up studies in the Romanian population. This study is
the first step towards improving our understanding of the genetic
particularities of this pathology in Romania and provides new
insights for the scientific community studying the genetic epidemiol-
ogy of LS.
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